Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Eli Lilly has launched its Mounjaro KwikPen in India, priced at $160 for the starting dose, targeting treatment for adults with type 2 diabetes and obesity. This move intensifies competition with Novo Nordisk in the GLP-1 drug market. Following a 13% drop in its share price amid market concerns, Eli Lilly's CEO purchased $1 million worth of stock, signaling confidence in the company's prospects. Both Eli Lilly and Novo Nordisk, along with Pfizer, are also seeking to expand their presence in China's pharmaceutical market by having their drugs included in Beijing's new commercial health insurance catalog, which has initially screened 121 drugs.
Pfizer $PFE, Eli Lilly $LLY, and Novo Nordisk $NVO aim to expand in China's pharma market by getting their drugs into Beijing's new commercial health insurance catalog, reports Bloomberg. 121 drugs have passed the initial screening.
Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry https://t.co/uAdUec22NL https://t.co/uAdUec22NL
$NVO $LLY - A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall https://t.co/f1XDVuqMsh
